Skip to main content

Analysts Offer Insights on Financial Companies: BlackRock (BLK) and State Street (STT)

Tipranks - Wed Feb 18, 9:08AM CST

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on BlackRock (BLKResearch Report) and State Street (STTResearch Report) with bullish sentiments.

President's Day Sale - 70% Off

BlackRock (BLK)

In a report released today, Craig Siegenthaler from Bank of America Securities maintained a Buy rating on BlackRock. The company’s shares closed last Tuesday at $1062.46, close to its 52-week high of $1084.22.

According to TipRanks.com, Siegenthaler is a 5-star analyst with an average return of 17.7% and a 62.6% success rate. Siegenthaler covers the Financial sector, focusing on stocks such as Figure Technology Solutions, Inc. Class A, Intercontinental Exchange, and Apollo Global Management. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BlackRock with a $1341.78 average price target.

See Insiders’ Hot Stocks on TipRanks >>

State Street (STT)

Morgan Stanley analyst Manan Gosalia maintained a Buy rating on State Street today and set a price target of $172.00. The company’s shares closed last Tuesday at $127.93.

According to TipRanks.com, Gosalia is a 4-star analyst with an average return of 9.2% and a 60.5% success rate. Gosalia covers the Financial sector, focusing on stocks such as Zions Bancorporation National Association, Valley National Bancorp, and Bank of New York Mellon. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for State Street with a $144.79 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.